Dr. Armstrong’s Center of Excellence
“I am excited to launch a phase 3 clinical trial with my colleagues to establish D’OXYVA’s safety and efficacy profile and help patients with diabetic foot ulcers.”
–David Armstrong, DPM, PhD
Register to participate in the Phase 3 trial with diabetic foot ulcers.
About Dr. David Armstrong
Dr. Armstrong is Professor of Surgery at the University of Southern California. Dr. Armstrong holds a Masters of Science in Tissue Repair and Wound Healing from the University of Wales College of Medicine and a PhD from the University of Manchester College of Medicine, where he was appointed Visiting Professor of Medicine. He is founder and co-Director of the Southwestern Academic Limb Salvage Alliance (SALSA).
Dr. Armstrong has produced more than 475 peer-reviewed research papers in dozens of scholarly medical journals as well as over 80 book chapters. He is co-Editor of the American Diabetes Association’s (ADA) Clinical Care of the Diabetic Foot, now in its third edition.
Dr. Armstrong was selected as one of the first six International Wound Care Ambassadors and is the recipient of numerous awards and degrees by universities and international medical organizations including the inaugural Georgetown Distinguished Award for Diabetic Limb Salvage. In 2008, he was the 25th and youngest-ever member elected into the Podiatric Medicine Hall of Fame. He was the first surgeon to be named University Distinguished Outreach Professor at the University of Arizona. He was the first podiatric surgeon to become a member of the Society of Vascular Surgery and the first US podiatric surgeon named fellow of the Royal College of Surgeons, Glasgow. He is the 2010 and youngest ever recipient of the ADA’s Roger Pecoraro Award, the highest award given in the field.
Dr. Armstrong is past Chair of Scientific Sessions for the ADA’s Foot Care Council, and a past member of the National Board of Directors of the American Diabetes Association. He sits on the Infectious Disease Society of America’s (IDSA) Diabetic Foot Infection Advisory Committee and is the US delegate to the International Working Group on the Diabetic Foot. Dr. Armstrong is the founder and co-Chair of DFCon, the largest annual symposium on the diabetic foot in the world.
About the Clinical Trial
We are excited to inform you about this unique opportunity that Circularity recently has confirmed Dr. Armstrong’s prominent clinic in Los Angeles, CA as part of its pivotal Phase 3 multi-center, multi-country human clinical trials for rapid treatment and closure of diabetic foot ulcer wounds and as one of its centers of excellence.
This further secures Circularity’s ambitions to obtain updated FDA-clearance on its platform patented and patent pending FDA-approved drug (pharma-CO2) together with its patented non-invasive transdermal drug delivery systems even sooner than originally planned on a fast-track FDA program in several countries at the same time.
Every case completed and publicized each month and quarter is expected to generate enough buzz so we can spread the news of D’OXYVA’s power to ever-more suffering people in need.